Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Heartflow, Inc. (NASDAQ:HTFL) have received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $43.4286.

A number of equities research analysts have recently weighed in on HTFL shares. Canaccord Genuity Group boosted their price target on Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Wells Fargo & Company upped their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Friday. Piper Sandler restated an “overweight” rating and issued a $45.00 target price (up from $38.00) on shares of Heartflow in a research note on Friday. Finally, William Blair began coverage on Heartflow in a research report on Monday, May 4th. They issued an “outperform” rating on the stock.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $28.31, for a total value of $638,730.22. Following the sale, the chief executive officer directly owned 436,280 shares of the company’s stock, valued at $12,351,086.80. This represents a 4.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 106,586 shares of company stock worth $3,269,343. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the fourth quarter valued at $27,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow in the 4th quarter valued at about $45,000. Legal & General Group Plc purchased a new stake in shares of Heartflow in the third quarter worth about $59,000. Essential Partners LLC acquired a new stake in Heartflow during the first quarter worth about $57,000. Finally, Strs Ohio acquired a new position in Heartflow in the fourth quarter valued at approximately $99,000.

Heartflow Price Performance

Shares of HTFL stock opened at $41.94 on Tuesday. The company has a market cap of $3.62 billion and a P/E ratio of -22.92. The stock’s 50-day moving average is $29.35 and its 200 day moving average is $27.85. Heartflow has a 1-year low of $20.13 and a 1-year high of $43.28.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.The firm had revenue of $64.08 million during the quarter. The company’s revenue was up 47.7% on a year-over-year basis. On average, analysts anticipate that Heartflow will post -0.82 EPS for the current year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.